These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31925810)

  • 1. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
    Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
    [No Abstract]   [Full Text] [Related]  

  • 2. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
    Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
    Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation in TET2 in myeloid cancers.
    Tefferi A; Lim KH; Levine R
    N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
    [No Abstract]   [Full Text] [Related]  

  • 6. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
    Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.
    Lin HC; Hwang DY; Lim KH
    Med Oncol; 2016 Aug; 33(8):92. PubMed ID: 27418193
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mutation of tet2 gene and malignant blood disease].
    Qian XF; Shen YF; Zhang SJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
    Kosmider O; Gelsi-Boyer V; Cheok M; Grabar S; Della-Valle V; Picard F; Viguié F; Quesnel B; Beyne-Rauzy O; Solary E; Vey N; Hunault-Berger M; Fenaux P; Mansat-De Mas V; Delabesse E; Guardiola P; Lacombe C; Vainchenker W; Preudhomme C; Dreyfus F; Bernard OA; Birnbaum D; Fontenay M;
    Blood; 2009 Oct; 114(15):3285-91. PubMed ID: 19666869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutations in TET2 in myeloid cancers].
    Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
    Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes.
    Siitonen T; Savolainen ER; Koistinen P
    Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
    Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
    Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
    Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M
    Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
    Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.
    Ernst T; Chase A; Zoi K; Waghorn K; Hidalgo-Curtis C; Score J; Jones A; Grand F; Reiter A; Hochhaus A; Cross NC
    Haematologica; 2010 Sep; 95(9):1473-80. PubMed ID: 20421268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia.
    Coutinho DF; Diniz C; Filgueiras RL; Baptista RL; Ayres-Silva JP; Monte-Mór BC; Bonamino MH; Zalcberg IR
    Genet Mol Res; 2013 Nov; 12(4):5858-62. PubMed ID: 24301955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of mutant TET2 on clonality and subclonal hierarchy.
    Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
    Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.